The Fourth Annual Meeting of the European Vascular Genomics Network (EVGN, www.evgn.org), Network of excellence on cardiovascular disease, opened yesterday, September 17th, in the prestigious venue of the University of Bristol (UK), that made available to the event two historical buildings: the Wills Memorial Building, inaugurated by King George V and Queen Mary, and the Merchant Venturers Building.
Run jointly with the European Vascular Biology Organization (EVBO) and the British Atherosclerosis Society and articulated over a three day period (September 17-20), the EVGN Meeting will take place in parallel with the 4th European Meeting on Vascular Biology and Medicine (EMVBM), gathering more than 400 scientists from all over Europe with representatives from the rest of the world. Cardiologists and diabetes researchers, as well as hematologists, thrombosis scientists, gene therapists and oncologists will alternate their presentations to show new data and debate perspectives on the therapeutic side.
“Once again as we did in 2005 – said the President of EVBO Professor Andrew Newby – the simultaneous presence of renowned scientists with different expertise and competence is a unique chance to confront news and views on controversial aspects of vascular disease, an elusive but deadly disease, and to enhance the productivity and the competitiveness of the European scientific community at large”.
The agenda is more than full: 10 plenary speakers, a selection of 45 oral presentations and almost 200 posters complete a rich and comprehensive programme. And tomorrow, Sept. 19, the Young Investigator Award will be assigned to a young distinguished researcher, with the aim of encouraging his/her investigations in years to come.
The opening Hugh Sinclair lecture that concluded the first day of the Meeting was presented by Professor Goran K. Hansson, from the Karolinska Hospital, Center for Molecular Medicine, who offered an elegant state-of-the-art summary of atherosclerosis, with an eye to the most appealing therapeutic perspective: a vaccine against this immune disease. “The current knowledge of atherosclerosis has markedly changed over the latest years” said Hansson, who is a leading scientists in the immunology field. “Today we know that atherosclerosis is an inflammatory disease with both a systemic association and a genetic involvement. Inside the plaques there is a strong immune activity, and day after day we learn more and more about the immunopathogenetic mechanisms with the aid of mouse models that mimic the disease in humans. But we are still a few steps away from a human trial”. There are three unresolved issues. We need: to find the proper antigen for immunization (a good candidate is the LDL particle, Low Density Lipoprotein or bad cholesterol); to clarify the mechanism of action (it has to be decided whether the vaccine wants to reduce bad circulating lipoproteins or act upon immune cells that create inflammation in the artery); finally, we have to identify the optimal administration route. “When we overcome these bottlenecks, we will get to the vaccine.”
Today, September 18th, the EVGN scientists will address some of the most critical topics for cardiovascular disease:
• strategies to modulate angiogenesis (the growth of blood vessels which is necessary to avoid tissue necrosis after ischemia);
• ways to target atherosclerotic plaques;
• the clinical experience in the acute myocardial infarction
“Most of the convened scientists – commented Professor Newby – are at the fore front of the research. We expect interesting news from this fourth EVGN Meeting. We also want to start proceeding on new therapeutic avenues, to improve scientists’ interactions and encourage young talents”.
The European Vascular Genomics Network (EVGN) is the first Network of Excellence on cardiovascular disease funded by the European Commission under the 6th Framework Programme "Life sciences, genomics and biotechnology for health" (Contract Number: LSHM-CT-2003-503254).
The conference is supported by an unrestricted educational grant from Laboratoires SERVIER.
Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine
University of Maryland researchers contribute to historic detection of gravitational waves and light created by event
On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...
Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.
Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....
Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).
When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...
Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.
How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...
Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.
It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...
17.10.2017 | Event News
10.10.2017 | Event News
10.10.2017 | Event News
19.10.2017 | Materials Sciences
19.10.2017 | Materials Sciences
19.10.2017 | Physics and Astronomy